NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,188.63 -447.59 (-2.28%) CRUDE OIL
79.29 -0.51 (-0.64%) GOLD FUTURES
2,418.70 -19.80 (-0.81%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
56,089.30 +3,417.67 (+6.49%)
AZN Oct 2024 65.000 call
- Business Wire
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
CAMBRIDGE, England, May 21, 2024--Investor Day 2024
- Benzinga
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at
- Benzinga
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
A Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc (NYSE:PFE) $107.5 million in damages, concluding that AstraZeneca’s blockbuster lung cancer drug, Tagrisso, infringed on Pfizer’s Wyeth unit’s patent rights. The jury found that AstraZeneca’s Tagrisso violated two patents held by Pfizer, which cover methods for treating cancer using the breast cancer drug Nerlynx. Also Read: Double Good News For AstraZeneca’s Breast Cancer Drugs. Puma Biotechnology Inc (
